文献速递妇科

选择性孕激素受体调节剂在子宫肌瘤管理中的过去、现在和未来

The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
PubMed 文献 · Am J Obstet Gynecol · 2017-12-21

子宫肌瘤在育龄女性中常见,影响生活质量和生育。许多国际妇产科协会的循证指南尚未反映选择性孕激素受体调节剂(SPRM)类的最新临床证据和已批准适应证。本文旨在通过回顾SPRM的历史发展、基于现有数据的使用最佳实践及未来潜在用途,分享欧洲和加拿大使用SPRM的临床经验。

要点

  • 许多国际妇产科协会的子宫肌瘤指南尚未反映SPRM类的最新证据和已批准适应证。
  • 本文分享欧洲和加拿大使用SPRM的临床经验。
  • 文章回顾SPRM历史、当前最佳实践和未来在子宫肌瘤及其他妇科疾病中的潜在用途。

核心结论

  • 许多国际妇产科协会的循证指南尚未反映SPRM类的最新临床证据和已批准适应证。

研究设计与样本

  • 本文为综述,旨在通过回顾SPRM的历史发展、当前最佳实践和未来潜在用途,分享欧洲和加拿大使用SPRM的临床经验。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Uterine fibroids are common in women of reproductive age and can have a significant impact on quality of life and fertility. Although a number of international obstetrics/gynecology societies have issued evidence-based clinical practice guidelines for the management of symptomatic uterine fibroids, many of these guidelines do not yet reflect the most recent clinical evidence and approved indication for one of the key medical management options: the selective progesterone receptor modulator class. This article aims to share the clinical experience gained with selective progesterone receptor modulators in Europe and Canada by reviewing the historical development of selective progesterone receptor modulators, current best practices for selective progesterone receptor modulator use based on available data, and potential future uses for selective progesterone receptor modulators in uterine fibroids and other gynecologic conditions.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Singh SS, Belland L, Leyland N, et al. The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids. Am J Obstet Gynecol. 2017. PMID: 29274830. doi:10.1016/j.ajog.2017.12.206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。